592 related articles for article (PubMed ID: 23676106)
41. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
42. [Effect of Acupuncture on Reproductive Endocrine and p-Akt Protein Expression in Polycystic Ovary Syndrome Rats with Insulin Resistance].
Zhang Y; Cao S; Wen SD; Re ZC; Li YP; Tong L
Zhen Ci Yan Jiu; 2018 Oct; 43(10):622-6. PubMed ID: 30365256
[TBL] [Abstract][Full Text] [Related]
43. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
44. [Effect of polycystic ovary syndrome treated with the periodic therapy of acupuncture].
Yang D; Zhao M; Tan J
Zhongguo Zhen Jiu; 2017 Aug; 37(8):825-829. PubMed ID: 29231341
[TBL] [Abstract][Full Text] [Related]
45. Endocrine and metabolic characteristics of polycystic ovary syndrome in Chinese women with different phenotypes.
Xu X; Shi Y; Cui Y; Ma J; Che L; Chen ZJ
Clin Endocrinol (Oxf); 2012 Mar; 76(3):425-30. PubMed ID: 21815904
[TBL] [Abstract][Full Text] [Related]
46. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Zhang J; Xing C; Cheng X; He B
Front Endocrinol (Lausanne); 2022; 13():1003238. PubMed ID: 36147577
[TBL] [Abstract][Full Text] [Related]
47. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome.
Elting MW; Korsen TJ; Schoemaker J
Clin Endocrinol (Oxf); 2001 Dec; 55(6):767-76. PubMed ID: 11895219
[TBL] [Abstract][Full Text] [Related]
48. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
49. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Patel R; Shah G
Curr Med Res Opin; 2017 Sep; 33(9):1545-1557. PubMed ID: 28058854
[TBL] [Abstract][Full Text] [Related]
50. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of Tung's acupuncture for sex hormones in polycystic ovary syndrome: A randomized controlled trial.
Cao Y; Chen H; Zhao D; Zhang L; Yu X; Zhou X; Liu Z
Complement Ther Med; 2019 Jun; 44():182-188. PubMed ID: 31126554
[TBL] [Abstract][Full Text] [Related]
52. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
53. Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial.
Wen Q; Hu M; Lai M; Li J; Hu Z; Quan K; Liu J; Liu H; Meng Y; Wang S; Wen X; Yu C; Li S; Huang S; Zheng Y; Lin H; Liang X; Lu L; Mai Z; Zhang C; Wu T; Ng EHY; Stener-Victorin E; Ma H
Hum Reprod; 2022 Mar; 37(3):542-552. PubMed ID: 34907435
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
[TBL] [Abstract][Full Text] [Related]
55. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
Sam S; Scoccia B; Yalamanchi S; Mazzone T
Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
[TBL] [Abstract][Full Text] [Related]
56. Kuntai capsules improve glucolipid metabolism in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.
Liang R; Liu Z; Li P; Fan P; Xu L; Sun X; Peng J; Peng X; Zhang M
Medicine (Baltimore); 2019 Sep; 98(39):e16788. PubMed ID: 31574794
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
Sun X; Wu X; Zhou Y; Yu X; Zhang W
Med Sci Monit; 2015 Aug; 21():2547-52. PubMed ID: 26314870
[TBL] [Abstract][Full Text] [Related]
58. Can metformin reduce insulin resistance in polycystic ovary syndrome?
Açbay O; Gündoğdu S
Fertil Steril; 1996 May; 65(5):946-9. PubMed ID: 8612854
[TBL] [Abstract][Full Text] [Related]
59. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
60. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
